Dr. Thrasher discusses the recent ADA and AACE guidelines for treating patients, and the benefits of a DPP-4 for patients. More videos with Dr. Thrasher: James R. Thrasher, MD, Introduction Education, Nutrition, Physical Activity What Do You Do to Help Your Patients with Type 2 Diabetes? Difficulties with Getting Patients …
Read More »AACE: The First Study to Show That an Ethnic Group Can Gain Benefits from a DPP-4 Compound
The dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta, Boehringer Ingelheim and Lilly) is associated with significant improvements in glycated hemoglobin (HbA1c) in black patients with type 2 diabetes….
Read More »New Possible DPP-4/TZD Combo for Jan 2012
Takeda announced that the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone.…
Read More »DPP-4 Inhibitor Survey
During my frequent visits to prescribers’ offices I get a chance to see their prescribing habits. When it comes to DPP-4 inhibitors, medical professionals seem to have similar opinions on how to use each of the drugs from this class. But to test this theory, we contacted 25 primary care …
Read More »Role of DPP-4 Inhibitors in Clinical Practice
The dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and increase the incretin effect in patients with type 2 diabetes. In clinical practice they are associated with significant reductions in HbA1c, no …
Read More »No Increased CVD Events with DPP-4 Inhibitors
Offering a rare glimmer of good cardiovascular-disease news for a diabetes drug, a new meta-analysis suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors, at worst, do not increase the risk of cardiovascular events and, at best, may even have a protective effect.…
Read More »ADA: New and Novel DPP-4 Reduces HbA1c Alone and in Combination
A novel dipeptidyl peptidase 4 (DPP-4) inhibitor — linagliptin — showed improved glycemic control as monotherapy, as an add-on, and in combination with other oral diabetes medications, researchers reported….
Read More »The Effect of Metformin on DPP-4 Activity in Type 2 Diabetes
DPP-4 activity suppressed by metformin ……
Read More »Alogliptin (DPP-4) Inhibitor Delayed by FDA
The FDA decision will delay the drug’s possible launch by at least two years, according to company officials.
Read More »The Next DPP-4 Inhibitor Onglyza™ Passes CVD Review: Coming Soon
An FDA panel voted 10-2 that the investigational diabetes drug saxagliptin (Onglyza) does not put Type 2 diabetes patients at an increased risk for cardiovascular events, but wants drugmaker Bristol-Myers Squibb to
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.